XML 71 R43.htm IDEA: XBRL DOCUMENT

RESTATEMENT (Tables)

12 Months Ended

Sep. 30, 2022

RESTATEMENT

Schedule of impacts of error corrections

The following table summarizes the impacts of these error corrections on the Company's financial statements for each of the periods presented below:


i. Balance sheet
		Impact of correction of error
December 31, 2021 (Unaudited)		As previously reported		Adjustments		As restated

Total assets		45,413,291		-		45,413,291

Warrant liabilities		-		119,597,612		119,597,612
Other		55,904,761		-		55,904,761
Total liabilities		55,904,761		119,597,612		175,502,373

Accumulated deficit		(186,838,587)		(119,597,612)		(306,436,199)
Others		176,347,117		-		176,347,117
Total deficiency in shareholders' equity		(10,491,470)		(119,597,612)		(130,089,082)


		Impact of correction of error
March 31, 2022 (Unaudited)		As previously reported		Adjustments		As restated

Total assets		105,206,180		-		105,206,180

Warrant liabilities		-		203,955,631		203,955,631
Other		55,649,512		-		55,649,512
Total liabilities		55,649,512		203,955,631		259,605,143

Accumulated deficit		(219,411,972)		(411,632,707)		(631,044,679)
Additional Paid in Capital		268,667,769		207,677,076		476,344,845
Others		300,871		-		300,871
Total deficiency in shareholders' equity		49,556,668		(203,955,631)		(154,398,963)


		Impact of correction of error
June 30, 2022 (Unaudited)		As previously reported		Adjustments		As restated

Total assets		84,264,830		-		84,264,830

Warrant liabilities		-		6,126,358		6,126,358
Series E Options liability		23,085,886		(23,085,886)		-
Other		42,023,055		-		42,023,055
Total liabilities		65,108,941		(16,959,528)		48,149,413

Accumulated deficit		(278,883,532)		(357,008,298)		(635,891,830)
Additional Paid in Capital		297,540,727		373,967,826		671,508,553
Others		498,694		-		498,694
Total deficiency in shareholders' equity		19,155,889		16,959,528		36,115,417


ii. Statement of operations
		Impact of correction of error - year
Quarter ended December 31, 2021 (Unaudited)		As previously reported		Adjustments		As restated

Loss from operations		(14,058,407)		-		(14,058,407)


Other financing costs - initial recognition of warrants at fair value		-		(108,979,229)		(6,282,494)
Revaluation of warrants		-		(10,618,382)		(10,618,382)
Others		(22,405,532)		-		(22,405,532)
Other income (expense)		(22,405,532)		(119,597,612)		(142,003,144)
Net loss		(36,463,939)		(119,597,612)		(156,061,551)
Loss per share		(2.09)				(8.93)
Weighted average common shares outstanding		17,471,173				17,471,173


		Impact of correction of error - quarter						Impact of correction of error - year to date
Quarter ended March 31, 2022 (Unaudited)		As previously reported		Adjustments		As restated		As previously reported		Adjustments		As restated

Loss from operations		(30,452,870)		-		(30,452,870)		(44,511,277)		-		(44,511,277)

Other financing costs - initial recognition of warrants at fair value
Loss on financing		-		(160,364,949)		(160,364,949)		-		(269,344,178)		(269,344,178)
Revaluation of warrants		-		(131,670,146)		(131,670,146)		-		(142,288,528)		(142,288,528)
Others		(2,120,515)		-		(2,120,515)		(24,526,046)		-		(24,526,046)
Other income (expense)		(2,120,515)		(292,035,095)		(294,155,610)		(24,526,046)		(411,632,707)		(436,158,753)
Net loss		(32,573,385)		(292,035,095)		(324,608,480)		(69,037,323)		(411,632,707)		(480,670,030)
Deemed dividend on preferred stock		-		(32,735,345)		(32,735,345)		-		(32,735,345)		(32,735,345)
Net loss attributable to common stockholders		(32,573,385)		(324,770,440)		(357,343,825)		(69,037,323)		(444,368,052)		(513,405,375)
Loss per share - continuing operations		(0.63)				(6.95)		(1.99)				(14.82)
Weighted average common shares outstanding		51,392,988				51,392,988		34,639,857				34,639,857

		Impact of correction of error - quarter						Impact of correction of error - year to date
Quarter ended June 30, 2022 (Unaudited)		As previously reported		Adjustments		As restated		As previously reported		Adjustments		As restated

Loss from operations		(18,221,165)		-		(18,221,165)		(62,732,442)		-		(62,732,442)

Other financing costs - initial recognition of warrants at fair value
Loss on financing		-		-		-		-		(269,344,178)		(269,344,178)
Revaluation of warrants		-		31,538,523		31,538,523		-		(110,750,005)		(110,750,005)
Series E Options liability		(23,085,886)		23,085,886		-		(23,085,886)		23,085,886		-
Others		(41,250,395)		-		(41,250,395)		(65,776,422)		-		(65,776,422)
Other income (expense)		(64,336,281)		54,624,409		(9,711,872)		(88,862,308)		(357,008,298)		(445,870,606)
Net loss		(82,557,446)		54,624,409		(27,933,037)		(151,594,750)		(357,008,298)		(508,603,048)
Deemed dividend on preferred stock		-		-		-		-		(32,735,345)		(32,735,345)
Net loss attributable to common stockholders		(82,557,446)		54,624,409		(27,933,037)		(151,594,750)		(389,743,643)		(541,338,393)
Loss per share - continuing operations		(0.22)				(0.07)		(0.89)				(3.19)
Weighted average common shares outstanding		376,786,685				376,786,685		169,531,688				169,531,688